Everfront Biotech receives FDA agreement for Cerebraca® Wafer trial
The Phase IIb/III study will evaluate recurrent glioblastoma patients and may support future discussions about Breakthrough Therapy Designation.
Latest Everfront Biotech News & Updates
See the latest news and media coverage for EFB. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
Latest news about Everfront Biotech (EFB)
In short: Everfront Biotech received FDA agreement for a Phase IIb/III Cerebraca Wafer trial.
Company announcements
EFB advances to Top 5 of PharmaEssentia Innovation Award
Cerebraca Wafer selected as finalist, validating localized drug delivery for glioblastoma; phase IIb/III trial underway.
EFB announces clinical results for Cerebraca® Wafer at ASCO 2026
The wafer showed potential to reverse chemoresistance and a Phase IIb/III trial has started.
Everfront Biotech receives 2023 National Innovation Award
The award recognizes Cerebraca® Wafer for combating glioblastoma. Phase IIa trials concluded in 2023; Fast Track approved. Plans FDA communication in 2024.
Media coverage
Everfront Biotech Files for Proposed IPO
Everfront Biotech (EFB) has filed for a proposed IPO. The company describes itself as: "We are a clinical stage biopharmaceutical company dedicated to the discovery...
Never miss news about EFB
Track EFB and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
INOVIO
Nano Labs
SharkNinja
NRx
Ropes & Gray
HighTech Kaunas
inretrn
Poundland
Farrer & Co
Specialfastigheter
SISAB
Hemsö
Stenvalvet
Liljewall
Veidekke
Locum
NCC
Kriminalvården
Archus
Nyréns
Peab
MVB
VGR fastigheter
AIX
ByggDialog
Tengbom
LINK
Dynacon
Delphidata
Waystream
Netnod
Open Infra
PENN Entertainment
BrandCrowd
Itancia
Paul, Weiss